Lectin-Fusion for LSDs (e.g., MPS I, Pompe)

About SylamoreBio

SylamoreBio is a private, pre-clinical stage biotech leveraging a proprietary RTB-lectin-based delivery platform to target CNS and other challenging tissues. The technology uses a sugar-binding lectin for receptor-independent cellular uptake, potentially enabling effective delivery of enzymes, antibodies, and RNAs across the blood-brain barrier and into avascular tissues like bone. The company is addressing a critical unmet need in lysosomal storage disorders and other conditions where current therapies are hindered by delivery challenges and anti-drug antibodies.

Therapeutic Areas